Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Exclusion Criteria

• •Known histological transformation from CLL to an aggressive lymphoma (ie, Richter transformation)
• •Known presence of myelodysplastic syndrome
• •Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of randomization
• •Ongoing liver injury
• •History of non-infectious pneumonitis
• •Ongoing inflammatory bowel disease
• •History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
• •Ongoing immunosuppressive therapy other than corticosteroids
• •Received last dose of study drug on another therapeutic clinical trial within 30 days prior to randomization